Drugs / ENN0403
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05506540 | Feb 2021 → May 2022 | — | EnnovaBio | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06708260 | Dec 2024 → Dec 2025 overdue | diabetic macular edema | EnnovaBio | Recruiting | No outcome recorded |
| Phase 2 | NCT06632613 | Nov 2024 → Feb 2026 overdue | acute kidney injury | EnnovaBio | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENN0403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06708260 ↗ |
| Route | Oral | “ENN0403 capsules for oral use” NCT05506540 ↗ |